Alzheimer’s Disease Classification Using Population-Referenced Brain Volumetric Percentiles
Highlights
- Population-referenced brain volumetric percentiles across 95 regions achieved excellent Alzheimer’s disease classification with AUC values exceeding 0.960 on ADNI internal validation, ADNI test, and independent Korean external validation datasets.
- The minimal validation gap of 0.018 between ADNI and Korean cohorts demonstrates robust model generalization across different populations, scanner protocols, and demographic compositions without requiring dataset-specific retraining.
- Percentile-based classification enables individual-level AD diagnosis without requiring longitudinal monitoring or age- and sex-matched control groups, addressing a major barrier to clinical translation of volumetric biomarkers.
- The dual-validation approach with external Korean cohort validation provides strong evidence that automated segmentation combined with population-referenced percentiles can serve as an accessible, cross-population neuroimaging tool for Alzheimer’s disease assessment.
Abstract
1. Introduction
2. Materials and Methods
2.1. Subjects
2.1.1. Reference Dataset
2.1.2. ADNI Dataset
2.1.3. Korean Dataset
2.2. Image Processing
2.3. Percentile Score Calculation
2.4. Classification Model Development
2.5. Model Validation and Evaluation
2.6. Statistical Analysis
3. Results
3.1. Subject Characteristics
3.2. Model Performance
3.3. Cross-Dataset Generalization
3.4. Feature Importance and Regional Contributions
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| AD | Alzheimer’s disease |
| ADNI | Alzheimer’s Disease Neuroimaging Initiative |
| ADRDA | Alzheimer’s Disease and Related Disorders Association |
| AUC | Area Under Curve |
| CN | Clinically Normal |
| CSF | Cerebrospinal Fluid |
| DC | Diencephalon |
| FN | False Negatives |
| FP | False Positives |
| MCI | Mild Cognitive Impairment |
| MMSE | Mini-Mental State Examination |
| MRI | Magnetic Resonance Imaging |
| NINCDS | National Institute of Neurological and Communicative Disorders and Stroke |
| ROC | Receiver Operating Characteristic |
| TN | True Negatives |
| TP | True Positives |
| WM | White Matter |
References
- Fischl, B. FreeSurfer. Neuroimage 2012, 62, 774–781. [Google Scholar] [CrossRef]
- Khadhraoui, E.; Nickl-Jockschat, T.; Henkes, H.; Behme, D.; Müller, S.J. Automated brain segmentation and volumetry in dementia diagnostics: A narrative review with emphasis on FreeSurfer. Front. Aging Neurosci. 2024, 16, 1459652. [Google Scholar] [CrossRef]
- Hedges, E.P.; Dimitrov, M.; Zahid, U.; Vega, B.B.; Si, S.; Dickson, H.; McGuire, P.; Williams, S.; Barker, G.J.; Kempton, M.J. Reliability of structural MRI measurements: The effects of scan session, head tilt, inter-scan interval, acquisition sequence, FreeSurfer version and processing stream. Neuroimage 2022, 246, 118751. [Google Scholar] [CrossRef]
- Henschel, L.; Conjeti, S.; Estrada, S.; Diers, K.; Fischl, B.; Reuter, M. FastSurfer—A Fast and Accurate Deep Learning Based Neuroimaging Pipeline. NeuroImage 2020, 219, 117012. [Google Scholar] [CrossRef]
- Rudolph, J.; Rueckel, J.; Döpfert, J.; Ling, W.X.; Opalka, J.; Brem, C.; Hesse, N.; Ingenerf, M.; Koliogiannis, V.; Solyanik, O.; et al. Artificial intelligence–based rapid brain volumetry substantially improves differential diagnosis in dementia. Alzheimer’s Dement. Diagn. Assess. Dis. Monit. 2024, 16, e70037. [Google Scholar] [CrossRef]
- Suh, P.S.; Jung, W.; Suh, C.H.; Kim, J.; Oh, J.; Heo, H.; Shim, W.H.; Lim, J.-S.; Lee, J.-H.; Kim, H.S.; et al. Development and validation of a deep learning-based automatic segmentation model for assessing intracranial volume: Comparison with NeuroQuant, FreeSurfer, and SynthSeg. Front. Neurol. 2023, 14, 1221892. [Google Scholar]
- Liu, M.; Li, F.; Yan, H.; Wang, K.; Ma, Y.; Shen, L.; Xu, M.; Alzheimer’s Disease Neuroimaging Initiative. A multi-model deep convolutional neural network for automatic hippocampus segmentation and classification in Alzheimer’s disease. Neuroimage 2020, 208, 116459. [Google Scholar] [CrossRef] [PubMed]
- Platero, C.; Tobar, M.C. A fast approach for hippocampal segmentation from T1-MRI for predicting progression in Alzheimer’s disease from elderly controls. J. Neurosci. Methods 2016, 270, 61–75. [Google Scholar] [CrossRef]
- Du, A.T.; Schuff, N.; Amend, D.; Laakso, M.P.; Hsu, Y.Y.; Jagust, W.J.; Yaffe, K.; Kramer, J.H.; Reed, B.; Norman, D.; et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 2001, 71, 441–447. [Google Scholar] [CrossRef]
- Leandrou, S.; Mamais, I.; Petroudi, S.; Kyriacou, P.A.; Reyes-Aldasoro, C.C.; Pattichis, C.S. Hippocampal and entorhinal cortex volume changes in Alzheimer’s disease patients and mild cognitive impairment subjects. In 2018 IEEE EMBS International Conference on Biomedical & Health Informatics (BHI); IEEE: New York, NY, USA, 2018; pp. 235–238. [Google Scholar]
- Ithapu, V.; Singh, V.; Lindner, C.; Austin, B.P.; Hinrichs, C.; Carlsson, C.M.; Bendlin, B.B.; Johnson, S.C. Extracting and summarizing white matter hyperintensities using supervised segmentation methods in Alzheimer’s disease risk and aging studies. Hum. Brain Mapp. 2014, 35, 4219–4235. [Google Scholar] [CrossRef] [PubMed]
- Tubi, M.A.; Feingold, F.W.; Kothapalli, D.; Hare, E.T.; King, K.S.; Thompson, P.M.; Braskie, M.N.; Alzheimer’s Disease Neuroimaging Initiative. White matter hyperintensities and their relationship to cognition: Effects of segmentation algorithm. Neuroimage 2020, 206, 116327. [Google Scholar]
- Woo, C.W.; Chang, L.J.; Lindquist, M.A.; Wager, T.D. Building better biomarkers: Brain models in translational neuroimaging. Nat. Neurosci. 2017, 20, 365–377. [Google Scholar] [CrossRef] [PubMed]
- Varoquaux, G. Cross-validation failure: Small sample sizes lead to large error bars. Neuroimage 2018, 180, 68–77. [Google Scholar] [CrossRef]
- Frisoni, G.B.; Fox, N.C.; Jack, C.R., Jr.; Scheltens, P.; Thompson, P.M. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010, 6, 67–77. [Google Scholar] [CrossRef]
- Nobis, L.; Manohar, S.G.; Smith, S.M.; Alfaro-Almagro, F.; Jenkinson, M.; Mackay, C.E.; Husain, M. Hippocampal volume across age: Nomograms derived from over 19,700 people in UK Biobank. NeuroImage Clin. 2019, 23, 101904. [Google Scholar] [CrossRef] [PubMed]
- Bethlehem, R.A.I.; Seidlitz, J.; White, S.R.; Vogel, J.W.; Anderson, K.M.; Adamson, C.; Adler, S.; Alexopoulos, G.S.; Anagnostou, E.; Areces-Gonzalez, A.; et al. Brain charts for the human lifespan. Nature 2022, 604, 525–533. [Google Scholar] [CrossRef] [PubMed]
- Falgàs, N.; Sánchez-Valle, R.; Bargalló, N.; Balasa, M.; Fernández-Villullas, G.; Bosch, B.; Olives, J.; Tort-Merino, A.; Antonell, A.; Muñoz-García, C.; et al. Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer’s disease patients: A comparison between visual and quantitative assessment. NeuroImage Clin. 2019, 23, 101927. [Google Scholar]
- Galton, C.J.; Patterson, K.; Graham, K.; Lambon-Ralph, M.A.; Williams, G.; Antoun, N.; Sahakian, B.J.; Hodges, J.R. Differing patterns of temporal atrophy in Alzheimer’s disease and semantic dementia. Neurology 2001, 57, 216–225. [Google Scholar] [CrossRef]
- Bateman, R.J.; Xiong, C.; Benzinger, T.L.S.; Fagan, A.M.; Goate, A.; Fox, N.C.; Marcus, D.S.; Cairns, N.J.; Xie, X.; Blazey, T.M.; et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med. 2012, 367, 795–804. [Google Scholar]
- Jack, C.R.; Knopman, D.S.; Jagust, W.J.; Shaw, L.M.; Aisen, P.S.; Weiner, M.W.; Petersen, R.C.; Trojanowski, J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010, 9, 119–128. [Google Scholar] [CrossRef]
- Marquand, A.F.; Rezek, I.; Buitelaar, J.; Beckmann, C.F. Understanding heterogeneity in clinical cohorts using normative models: Beyond case-control studies. Biol. Psychiatry 2016, 80, 552–561. [Google Scholar] [CrossRef]
- Marquand, A.F.; Kia, S.M.; Zabihi, M.; Wolfers, T.; Buitelaar, J.K.; Beckmann, C.F. Conceptualizing mental disorders as deviations from normative functioning. Mol. Psychiatry 2019, 24, 1415–1424. [Google Scholar] [CrossRef]
- Wolfers, T.; Doan, N.T.; Kaufmann, T.; Alnæs, D.; Moberget, T.; Agartz, I.; Buitelaar, J.K.; Ueland, T.; Melle, I.; Franke, B.; et al. Mapping the heterogeneous phenotype of schizophrenia and bipolar disorder using normative models. JAMA Psychiatry 2018, 75, 1146–1155. [Google Scholar] [CrossRef]
- Pinaya, W.H.L.; Scarpazza, C.; Garcia-Dias, R.; Vieira, S.; Baecker, L.; da Costa, P.F.; Redolfi, A.; Frisoni, G.B.; Pievani, M.; Calhoun, V.D.; et al. Using normative modelling to detect disease progression in mild cognitive impairment and Alzheimer’s disease in a cross-sectional multi-cohort study. Sci. Rep. 2021, 11, 15746. [Google Scholar] [CrossRef]
- Shim, J.H.; Baek, H.M.; Hoon, J. Regional Brain Volume Changes Across Adulthood: A Multi-Cohort Study Using MRI Data. Brain Sci. 2025, 15, 1096. [Google Scholar] [CrossRef]
- Mueller, S.G.; Weiner, M.W.; Thal, L.J.; Petersen, R.C.; Jack, C.R.; Jagust, W.; Trojanowski, J.Q.; Toga, A.W.; Beckett, L. Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimer’s Dement. 2005, 1, 55–66. [Google Scholar] [CrossRef] [PubMed]
- Mendiondo, M.S.; Ashford, J.W.; Kryscio, R.J.; Schmitt, F.A. Modelling mini mental state examination changes in Alzheimer’s disease. Stat. Med. 2000, 19, 1607–1616. [Google Scholar] [CrossRef]
- Doody, R.S.; Massman, P.; Dunn, J.K. A method for estimating progression rates in Alzheimer disease. Arch. Neurol. 2001, 58, 449–454. [Google Scholar] [CrossRef]
- Thompson, P.M.; Hayashi, K.M.; De Zubicaray, G.I.; Janke, A.L.; Rose, S.E.; Semple, J.; Hong, M.S.; Herman, D.H.; Gravano, D.; Doddrell, D.M.; et al. Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage 2004, 22, 1754–1766. [Google Scholar] [CrossRef] [PubMed]
- Klöppel, S.; Stonnington, C.M.; Chu, C.; Draganski, B.; Scahill, R.I.; Rohrer, J.D.; Fox, N.C.; Jack, C.R., Jr.; Ashburner, J.; Frackowiak, R.S. Automatic classification of MR scans in Alzheimer’s disease. Brain 2008, 131, 681–689. [Google Scholar] [CrossRef]
- Nestor, S.M.; Rupsingh, R.; Borrie, M.; Smith, M.; Accomazzi, V.; Wells, J.L.; Fogarty, J.; Bartha, R.; Alzheimer’s Disease Neuroimaging Initiative. Ventricular enlargement as a possible measure of Alzheimer’s disease progression validated using the Alzheimer’s disease neuroimaging initiative database. Brain 2008, 131, 2443–2454. [Google Scholar] [CrossRef]
- Apostolova, L.G.; Green, A.E.; Babakchanian, S.; Hwang, K.S.; Chou, Y.-Y.; Toga, A.W.; Thompson, P.M. Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer Disease. Alzheimer Dis. Assoc. Disord. 2012, 26, 17–27. [Google Scholar] [CrossRef]
- Ott, B.R.; Cohen, R.A.; Gongvatana, A.; Okonkwo, O.C.; Johanson, C.E.; Stopa, E.G.; Donahue, J.E.; Silverberg, G.D.; Alzheimer’s Disease Neuroimaging Initiative. Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer’s disease. J. Alzheimer’s Dis. 2010, 20, 647–657. [Google Scholar] [CrossRef]
- Koppelmans, V.; Silvester, B.; Duff, K. Neural mechanisms of motor dysfunction in mild cognitive impairment and Alzheimer’s disease: A systematic review. J. Alzheimer’s Dis. Rep. 2022, 6, 307–344. [Google Scholar] [CrossRef]
- Aggarwal, N.T.; Wilson, R.S.; Beck, T.L.; Bienias, J.L.; Bennett, D.A. Motor dysfunction in mild cognitive impairment and the risk of incident Alzheimer disease. Arch. Neurol. 2006, 63, 1763–1769. [Google Scholar] [CrossRef] [PubMed]
- Harasty, J.A.; Halliday, G.M.; Kril, J.J.; Code, C. Specific temporoparietal gyral atrophy reflects the pattern of language dissolution in Alzheimer’s disease. Brain 1999, 122, 675–686. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Braak, H.; Braak, E.; Bohl, J. Staging of Alzheimer-related cortical destruction. Eur. Neurol. 1993, 33, 403–408. [Google Scholar] [CrossRef]
- Poulin, S.P.; Dautoff, R.; Morris, J.C.; Barrett, L.F.; Dickerson, B.C.; Alzheimer’s Disease Neuroimaging Initiative. Amygdala atrophy is prominent in early Alzheimer’s disease and relates to symptom severity. Psychiatry Res. Neuroimaging 2011, 194, 7–13. [Google Scholar] [CrossRef]
- de Jong, L.W.; van der Hiele, K.; Veer, I.M.; Houwing, J.J.; Westendorp, R.G.J.; Bollen, E.L.M.; de Bruin, P.W.; Middelkoop, H.A.M.; van Buchem, M.A.; van der Grond, J. Strongly reduced volumes of putamen and thalamus in Alzheimer’s disease: An MRI study. Brain 2008, 131, 3277–3285. [Google Scholar] [CrossRef]
- Cousins, D.A.; Burton, E.J.; Burn, D.; Gholkar, A.; McKeith, I.G.; O’Brien, J.T. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer’s disease: An MRI study. Neurology 2003, 61, 1191–1195. [Google Scholar] [PubMed]
- Looi, J.C.L.; Svensson, L.; Lindberg, O.; Zandbelt, B.B.; Östberg, P.; Örndahl, E.; Wahlund, L.-O. Putaminal volume in frontotemporal lobar degeneration and Alzheimer disease: Differential volumes in dementia subtypes and controls. Am. J. Neuroradiol. 2009, 30, 1552–1560. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Greene, S.J.; Killiany, R.J.; Alzheimer’s Disease Neuroimaging Initiative. Subregions of the inferior parietal lobule are affected in the progression to Alzheimer’s disease. Neurobiol. Aging 2010, 31, 1304–1311. [Google Scholar] [CrossRef] [PubMed]
- Jacobs, H.I.; Van Boxtel, M.P.; Uylings, H.B.; Gronenschild, E.H.; Verhey, F.R.; Jolles, J. Atrophy of the parietal lobe in preclinical dementia. Brain Cogn. 2011, 75, 154–163. [Google Scholar] [CrossRef]
- Evans, M.C.; Barnes, J.; Nielsen, C.; Kim, L.G.; Clegg, S.L.; Blair, M.; Leung, K.K.; Douiri, A.; Boyes, R.G.; Ourselin, S.; et al. Volume changes in Alzheimer’s disease and mild cognitive impairment: Cognitive associations. Eur. Radiol. 2010, 20, 674–682. [Google Scholar] [CrossRef] [PubMed]



| Dataset | Group | N | Age (Years) | Male, N (%) | Female, N (%) | MMSE |
|---|---|---|---|---|---|---|
| Reference Population | CN | 1833 | 21–90 | 970 (52.9) | 863 (47.1) | N/A |
| ADNI Cohort | CN | 690 | 71.8 ± 7.0 | 287 (41.6) | 403 (58.4) | 29.1 ± 1.1 |
| AD | 183 | 77.3 ± 6.1 | 98 (53.6) | 85 (46.4) | 22.6 ± 2.6 | |
| Korean Cohort | CN | 36 | 68.5 ± 7.1 | 19 (52.8) | 17 (47.2) | 28.0 ± 1.9 |
| AD | 36 | 67.8 ± 7.0 | 19 (52.8) | 17 (47.2) | 18.7 ± 5.9 |
| Evaluation Set | N (AD/CN) | AUC | Accuracy | Sensitivity | Specificity | Precision (AD) | F1-Score (AD) |
|---|---|---|---|---|---|---|---|
| Training (5-fold CV) | 523 (110/413) | 0.961 ± 0.012 | — | — | — | — | — |
| ADNI Validation | 175 (37/138) | 0.963 | 0.897 | 0.919 | 0.891 | 0.694 | 0.791 |
| ADNI Test | 175 (36/139) | 0.960 | 0.897 | 0.889 | 0.899 | 0.696 | 0.78 |
| Korean External | 72 (36/36) | 0.981 | 0.875 | 0.75 | 1 | 1 | 0.857 |
| Region | Coefficient | Region | Coefficient |
|---|---|---|---|
| Left inferior lateral ventricle | 1.995 | Left choroid plexus | −0.010 |
| Right precentral | 1.539 | Right pericalcarine | −0.028 |
| Right inferior lateral ventricle | 1.231 | Right supramarginal | −0.063 |
| Right superior temporal | 1.216 | Right transverse temporal | −0.081 |
| CSF | 0.956 | Right rostral middle frontal | −0.089 |
| Left superior temporal | 0.929 | Right caudate | −0.090 |
| Right isthmus cingulate | 0.927 | Right cuneus | −0.092 |
| Right cerebral white matter | 0.842 | Right pars orbitalis | −0.098 |
| Right lateral orbitofrontal | 0.739 | Left pars orbitalis | −0.113 |
| WM hypointensities | 0.717 | Left pallidum | −0.158 |
| Left paracentral | 0.671 | Right cerebellum cortex | −0.162 |
| Right postcentral | 0.670 | Left ventral DC | −0.166 |
| Left medial orbitofrontal | 0.623 | Right posterior cingulate | −0.179 |
| Right pallidum | 0.620 | Left-Thalamus | −0.209 |
| Left cerebellum cortex | 0.488 | Left precentral | −0.241 |
| Right-Thalamus | 0.422 | Right insula | −0.264 |
| Left pars opercularis | 0.391 | Left lateral orbitofrontal | −0.283 |
| Left superior parietal | 0.383 | 3rd Ventricle | −0.299 |
| Left accumbens area | 0.381 | Left precuneus | −0.302 |
| Left caudal anterior cingulate | 0.365 | Left parahippocampal | −0.304 |
| Right pars triangularis | 0.364 | Right medial orbitofrontal | −0.319 |
| Right rostral anterior cingulate | 0.347 | Left transverse temporal | −0.320 |
| Left inferior parietal | 0.345 | Left postcentral | −0.471 |
| Left insula | 0.336 | Left rostral anterior cingulate | −0.484 |
| Left cuneus | 0.329 | Right choroid plexus | −0.520 |
| Brain Stem | 0.308 | Right superior parietal | −0.556 |
| Right lateral occipital | 0.299 | Left cerebellum white matter | −0.584 |
| Right caudal middle frontal | 0.273 | Left posterior cingulate | −0.611 |
| Right fusiform | 0.272 | Left entorhinal | −0.619 |
| Right accumbens area | 0.261 | Right lateral ventricle | −0.655 |
| Left pars triangularis | 0.247 | Right precuneus | −0.667 |
| Right lingual | 0.228 | Left middle temporal | −0.671 |
| Right superior frontal | 0.225 | Left inferior temporal | −0.679 |
| Right pars opercularis | 0.213 | Left fusiform | −0.694 |
| Left cerebral white matter | 0.199 | Left lingual | −0.733 |
| Right cerebellum white matter | 0.196 | Left isthmus cingulate | −0.858 |
| Right putamen | 0.161 | Left caudal middle frontal | −0.886 |
| 4th Ventricle | 0.149 | Right inferior parietal | −1.002 |
| Right parahippocampal | 0.147 | Right inferior temporal | −1.002 |
| Left superior frontal | 0.135 | Right amygdala | −1.105 |
| Left rostral middle frontal | 0.132 | Left hippocampus | −1.119 |
| Right middle temporal | 0.111 | Left supramarginal | −1.192 |
| Right paracentral | 0.098 | Left putamen | −1.252 |
| Left pericalcarine | 0.090 | Right hippocampus | −1.292 |
| Left caudate | 0.083 | Right entorhinal | −1.327 |
| Right ventral DC | 0.082 | Left amygdala | −1.422 |
| Right caudal anterior cingulate | 0.050 | ||
| Left lateral ventricle | 0.017 | ||
| Left lateral occipital | 0.004 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Shim, J.H.; Baek, H.-M. Alzheimer’s Disease Classification Using Population-Referenced Brain Volumetric Percentiles. Brain Sci. 2026, 16, 334. https://doi.org/10.3390/brainsci16030334
Shim JH, Baek H-M. Alzheimer’s Disease Classification Using Population-Referenced Brain Volumetric Percentiles. Brain Sciences. 2026; 16(3):334. https://doi.org/10.3390/brainsci16030334
Chicago/Turabian StyleShim, Jae Hyuk, and Hyeon-Man Baek. 2026. "Alzheimer’s Disease Classification Using Population-Referenced Brain Volumetric Percentiles" Brain Sciences 16, no. 3: 334. https://doi.org/10.3390/brainsci16030334
APA StyleShim, J. H., & Baek, H.-M. (2026). Alzheimer’s Disease Classification Using Population-Referenced Brain Volumetric Percentiles. Brain Sciences, 16(3), 334. https://doi.org/10.3390/brainsci16030334
